Cash Flow Statement (Annual)

ADMA / ADMA Biologics Inc Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities
  Net Income Loss -5,903 -7,301 -15,527 -16,813 -17,970 -19,515 -43,759
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Depreciation And Amortization 220 182 211 248 470 470 2,692
    Gain Loss On Disposition Of Assets -1 -18 - - - 0 -10
    Share Based Compensation 23 627 888 1,248 1,711 1,250 1,562
    Amortization Of Debt Discount Premium 741 3 92 133 354 677 782
    Amortization Of License Revenue - 0 -44 -76 -127 -143 -143
  Increase Decrease In Operating Capital
    Increase Decrease In Accounts Receivable 0 -39 39 384 541 94 2,862
    Increase Decrease In Inventories -308 118 403 40 1,737 1,574 -589
    Increase Decrease In Prepaid Expense -6 49 191 -155 -33 203 941
    Increase Decrease In Other Operating Assets - -115 593 15 0 0 483
    Increase Decrease In Accounts Payable 40 -245 1,609 -938 309 477 2,812
    Increase Decrease In Accrued Liabilities 285 151 76 1,352 -200 417 614
    Increase Decrease In Other Current Liabilities - - - - - -31 -12
    Net Cash Provided By Used In Operating Activities -1,431 -6,904 -10,887 -14,705 -15,418 -18,269 -37,272
Net Cash Provided By Used In Investing Activities
  Proceeds From Sale Of Short Term Investments - - - - - - -
  Payments To Acquire Property Plant And Equipment 0 119 197 2,323 26 73 2,676
  Cash Acquired From Acquisition - - - - - 0 12,500
  Net Cash Provided By Used In Investing Activities -0 -119 -3,132 -4,041 -1,742 905 15,214
Net Cash Provided By Used In Financing Activities
  Repayments Of Notes Payable 200 200 - 0 15,301 0 20,000
  Proceeds From Issuance Or Sale Of Equity - - - - - - -
  Proceeds From Issuance Of Debt - - - - - 0 15,000
  Payments Of Debt Issuance Costs - 25 - 30 228 47 1,650
  Repayments Of Long Term Capital Lease Obligations - - - - - - -
  Repayments Of Debt And Capital Lease Obligations 10 10 12 13 14 15 17
  Net Cash Provided By Used In Financing Activities 1,290 19,471 27,633 9,795 10,402 16,838 60,751
  Cash And Cash Equivalents Period Increase Decrease -141 12,448 13,614 -8,950 -6,758 -526 38,693
  Cash - - - - - - -

Peers - Biological Products, Except Diagnostic Substances (Biotech) (2836)

Related News Stories

ADMA Biologics: Finish Line Ahead?

2018-09-06 seekingalpha
Today we will revisit ADMA Biologics, a small biotech whose stock has rallied recently to nearly $7.00 a share. (0-1)

ADMA Biologics: Buy Or Sell Before Bivigam PDUFA?

2018-08-31 seekingalpha
ADMA Biologics shares are already up 10% in less than a week since the trade was mentioned to subscribers of the premium Marketplace service. Shares have more upside ahead.

Revisiting ADMA Biologics

2018-08-24 seekingalpha
ADMA Biologics recently announced that the FDA had set an October 25, 2018, PDUFA Date for Bivigam.

Your Daily Pharma Scoop: ADMA Closer To PDUFA, Roche Proceeds, AstraZeneca Flunks

2018-07-30 seekingalpha
Discussion: ADMA Biologics (ADMA) announced that its request for amendment to BLA to relaunch BIVIGAM (intravenous immune globulin [human], 10%). PDUFA is on October 25. If the BLA is successful the product is expected to be launched in Q1 2019. Shares moved up 18% on this positive news. Following earlier FDA letters in 2014 and 2016 warning of the production facility of the drug, IVIG manufacturing facility was earlier shut down. (3-0)

ADMA Biologics: The Right Way To Fix Manufacturing

2018-06-14 seekingalpha
ADMA is in the third inning of a corporate turn-around. A manufacturing-related Warning Letter is preventing ADMA from reintroducing Bivigam to the market ($60m Revs/yr) and getting FDA approval for RI-002 (could be a $200m+/yr). While ADMA management has stated that their facility is inspection-ready, there has been a lot of uncertainty about the timing of the required FDA re-inspection and about the success of ADMA's efforts to fix the manufacturing issues. (5-5)

Your Daily Pharma Scoop: Secondaries Review June 4-11

2018-06-12 seekingalpha
Using a set of 3 criterion, we have singled out MEI Pharma's offering for an analysis. (169-14)

CUSIP: 000899104